Newsroom
Sorted by: Latest
-
PPG investiert in Testanlage für strahlungshärtende Beschichtungen in Marly, Frankreich
MARLY, Frankreich--(BUSINESS WIRE)--PPG (NYSE: PPG) hat heute die Einrichtung einer hochmodernen Testanlage für strahlungshärtende Beschichtungen in seinem F&E-Kompetenzzentrum in Marly, Frankreich, bekannt gegeben. In dieser Anlage können verschiedene Härtungstechnologien getestet werden, darunter Infrarot (Infrared, IR), Ultraviolett (LED, Excimer- und Bogenlampen) sowie Elektronenstrahl (Electron Beam, EB). Durch diese Investition wird das Unternehmen in der Lage sein, die Produktionsbed...
-
Irvine Tech Day Celebrates Irvine Innovation, Entrepreneurship & Community
IRVINE, Calif.--(BUSINESS WIRE)--Founders, investors, and industry leaders are coming together to promote and celebrate innovation, entrepreneurship, and community for the first-ever Irvine Tech Day on the second weekend of May. The packed agenda includes an exclusive Entrepreneurs Reception, a fireside chat, keynote speakers, panel discussions, pop-up market with startup businesses, and a big pitch contest amongst the top founders in the Irvine area. “Irvine continues to lead as a hub for tech...
-
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each,...
-
Veris Residential Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Veris Residential, Inc. - VRE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Veris Residential, Inc. (NYSE: VRE) to an investor consortium led by Affinius Capital in partnership with Vista Hill Partners. Under the terms of the proposed transaction, shareholders of Veris will receive $19.00 per share in cash. KSF is seeking to determine whether this consideration and the...
-
Robbins LLP Urges Investors Who Lost Money Investing in Medpace Holdings Inc. to Contact the Firm for Information About Leading the Class Action Against MEDP
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Medpace Holdings Inc. (NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.For more information, submit a form, email...
-
Clear Channel Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Clear Channel Outdoor Holdings, Inc. - CCO
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Clear Channel Outdoor Holdings, Inc. (NYSE: CCO) to Mubadala Capital, in partnership with TWG Global. Under the terms of the proposed transaction, shareholders of Clear Channel will receive $2.43 in cash for each share of Clear Channel that they own. KSF is seeking to determine whether this con...
-
Robbins LLP Encourages SLNO Stockholders to Contact the Firm for Information About the Class Action Against Soleno Therapeutics, Inc.
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prad...
-
KBRA Assigns Preliminary Ratings to GS Mortgage-Backed Securities Trust 2026-CES2 (GSMBS 2026-CES2)
NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 7 classes of mortgage-backed notes from GS Mortgage-Backed Securities Trust 2026-CES2 (GSMBS 2026-CES2), a $305.0 million RMBS transaction sponsored by Goldman Sachs Mortgage Company, entirely of closed-end second lien mortgages (CES; 100.0%). The underlying pool is seasoned approximately 8 months and comprises 3,854 loans, with AmeriSave Mortgage Corporation (66.4%) as the largest contributing originator. The collateral is characte...
-
AIHA Announces 2026 Hamilton Club Members
FALLS CHURCH, Va.--(BUSINESS WIRE)--Today, AIHA announced the members of the Hamilton Club, the Association’s exclusive partner program, for 2026. Hamilton Club membership is offered annually to companies that support AIHA's enterprise-wide initiatives through sponsorship, advertising, donations to the American Industrial Hygiene Foundation, career and pipeline development, and other contributions. As leaders in occupational and environmental health and safety, Hamilton Club members shape the f...
-
CarnoSyn® Brands Launches CarnoSyn® 4X, a Next-Generation Beta-Alanine for Sports Performance
CARLSBAD, Calif.--(BUSINESS WIRE)--Natural Alternatives International, Inc. (NAI) is launching CarnoSyn® 4X, the most advanced CarnoSyn® beta-alanine formulation to date. The ingredient delivers more than four times the bioavailability of standard beta-alanine without paresthesia, the tingling sensation often associated with beta-alanine usage. The proprietary, patent-pending ingredient gives sports nutrition brands a new way to deliver trusted CarnoSyn® beta-alanine benefits to a wider audienc...